SUPPLEMENTARY MATERIAL

Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi
Biologic/Targeted-synthetic DMARDs: US Observational Study of Patients With RA

Leslie R. Harrold ● Sean E. Connolly ● Keith Wittstock ● Joe Zhuo ● Sheila Kelly ● Thomas Lehman ● Ying Shan ● Sabrina Rebello ● Lin Guo ● Vadim Khaychuk

L.R. Harrold (corresponding author)
CorEvitas, LLC, Waltham, MA, USA and Associate Professor of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
e-mail: lharrold@corevitas.com

S.E. Connolly ● S. Kelly ● T. Lehman
Bristol Myers Squibb, Princeton, New Jersey, USA

K. Wittstock
US Immunology, Bristol Myers Squibb, Princeton, New Jersey, USA

J. Zhuo
Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA

Y. Shan ● L. Guo
Department of Biostatistics, CorEvitas, LLC, Waltham, Massachusetts, USA
S. Rebello
CorEvitas, LLC, Waltham, Massachusetts, USA (at the time of study)

V. Khaychuk
US Medical Immunology and Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA
Fig. S1 Adjusted mean improvement from baseline in mHAQ at 6 months after index date, by ACPA status, for abatacept or other non-TNFi b/tsDMARD initiators.*

*Adjusted for baseline covariates that differed by ACPA status ($P < 0.1$), not including factors that reduced the sample size by > 10% or were correlated with CDAI. Only the main variable category is listed below, although some variables were further broken down within each category:

- **Adjusted variables for the 2006–2019 cohort included**: for both drugs—BMI, marital status, smoking status, and prednisone use; for abatacept only—sex, race/ethnicity, insurance, college, work status, duration of RA, ACR functional class, history of malignancies, history of hypertension, history of serious infection, and current combination therapy; and for rituximab only—history of COPD.

- **Adjusted variables for the 2010–2019 cohort included**: for both drugs—race/ethnicity, insurance, work status, duration of RA, ACR functional class and CDAI; for abatacept only—sex, marital status, smoking status, history of malignancies, history of hypertension, history of serious infections, current combination therapy, morning stiffness, and initiation year; and for tocilizumab only—age, history of CVD, and prednisone use.

- **Adjusted variables for the 2012–2019 cohort included**: for both drugs—college, duration of RA, and CDAI; for abatacept only—race/ethnicity, BMI, marital status, work status and initiation year; and for tofacitinib only—history of CVD, history of serious infections, prior non-TNFi use, current combination therapy, and patient pain.

*Time period of initiation; refer to the Methods section for full details.

Δ change, ACR American College of Rheumatology, ACPA+ anti-citrullinated protein antibody positive (anti-CCP2 ≥ 20 U/mL), ACPA− anti-citrullinated protein antibody negative (anti-CCP2 < 20 U/mL), anti-CCP2 anti-cyclic citrullinated peptide-2, BMI body mass index, b/tsDMARD biologic or targeted-synthetic disease-modifying antirheumatic drug, CDAI Clinical Disease Activity Index, CI confidence interval, COPD chronic
obstructive pulmonary disease, csDMARD conventional-synthetic disease-modifying antirheumatic drug, CVD cardiovascular disease, mHAQ modified Health Assessment Questionnaire, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor.